0 works0 citations0 h-index

J.F. Merola

Southwestern Medical Center(US)Southwestern Medical CenterThe University of Texas Southwestern Medical Center(US)

Publications by Year

Research Areas

Psoriasis: Treatment and Pathogenesis, Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Autoimmune and Inflammatory Disorders Research, Health Systems, Economic Evaluations, Quality of Life

Most-Cited Works

→ OP0195 EFFICACY AND SAFETY OF SONELOKIMAB, A NOVEL IL-17A- AND IL-17F-INHIBITING NANOBODY®, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA): RESULTS FROM THE GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 ARGO TRIAL(2024)8 cited
→ OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial(2017)7 cited
→ AB0523 LONG-TERM SAFETY AND EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS AT 56 WEEKS FROM THE SELECT-PsA 1 STUDY(2021)7 cited
→ SAT0437 Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior tnf inadequate response(2017)4 cited
→ 83 Biib059, a monoclonal antibody targeting bdca2, demonstrates evidence of proof of biological activity in subjects with cutaneous lupus(2017)3 cited

→ Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study(2020)

3 cited

→ PMU15 RETROSPECTIVE STUDY EXAMINING HEALTH CARE UTILIZATION AND COSTS FOR PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS IN THE US(2020)2 cited

→ OP0112 In psoriatic arthritis fatigue is driven by inflammation, disease duration, and chronic pain: an observational danbio registry study(2017)1 cited

→ POS1030 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY BASELINE SKIN SEVERITY: A SUBGROUP ANALYSIS OF TWO PHASE III TRIALS(2021)1 cited

→ POS0105 DUAL INHIBITION OF IL-17A AND IL-17F WITH BIMEKIZUMAB DEMONSTRATED LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: FINAL 3-YEAR RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION(2025)1 cited